Skip to main content

MoneyWorks4Me

Speciality Medicines Ltd (544738)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544738 NSE: Trading | Small Cap | Speciality Medicines Share Price

₹140 0.00 (0.00%)

As on 02-Nov'26 16:59

Speciality Medicines Ltd (544738)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544738 NSE: Trading | Small Cap | Speciality Medicines Share Price

₹140 0.00 (0.00%)

As on 02-Nov'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹123 Cr.
Current Price
₹140
52-Week Low / High
₹121 / 381
TTM EPS
₹14.8
TTM Sales
₹75.3 Cr.
Book Value per Share
₹81
P/E Ratio
9.44
Lower than its 5-year historical median
Industry PE
42
Price to Book (P/B)
1.73
Lower than its 5-year historical median
Price to Sales (P/S)
1.63
Lower than its 5-year historical median
EV/EBITDA
7.24
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
25.60%
Outperforms industry median
Return on Capital Employed (ROCE)
25.26%
Outperforms industry median
Return on Assets (ROA)
19.27%
Outperforms industry median
Operating Profit Margin
15.7%
Outperforms industry median
Net Profit Margin
17.31%
Outperforms industry median
Gross Profit Margin
17.5%
Outperforms industry median
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
111.74%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
49.84%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
80.97%
Asset Quality
Promoter Holding
43.43%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹62 Cr.
Equity
₹8.8 Cr.
Face Value
₹10
All Time Low / High
₹121.10 / 381.20

Speciality Medicines stock performance

Key Ratios
mw4me loader

Check Before You Invest

Valuation

Somewhat Undervalued

Price Trend

Weak
Q.1 Is Speciality Medicines Ltd a good quality company?
Speciality Medicines Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Speciality Medicines Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Speciality Medicines Ltd vs industry peers?
Speciality Medicines Ltd revenue CAGR is 12.95%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Speciality Medicines Ltd?
Promoters hold 43.43% of the Speciality Medicines Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Speciality Medicines Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Speciality Medicines Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'22Mar'23Mar'24Mar'25TTM
ROCE % ⓘ69.8%52.4%37.7%34.3%-
Value Creation
Index ⓘ
4.02.71.71.5-

Growth Parameters ⓘ

Sales ⓘ40.423.227.558.375
Sales YoY Gr.--42.5%18.4%111.7%-
Adj EPS ⓘ4.74.45.610.914.8
YoY Gr.--6%25.6%96.4%-
BVPS (₹) ⓘ6.115.429.447.681
Adj Net
Profit ⓘ
1.51.72.8713
Cash Flow from Ops. ⓘ0.8-4.2-4.8-6.4-
Debt/CF from Ops. ⓘ1.5-0.9-0.6-0.8-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNANA13%111.7%
Adj EPS ⓘNANA32.4%96.4%
BVPSⓘNANA98%61.6%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity % ⓘ
76.643.327.130.723.1
Op. Profit
Mgn % ⓘ
5.615.419.215.7NAN
Net Profit
Mgn % ⓘ
3.77.310.31217.3
Debt to
Equity ⓘ
0.60.60.20.2-
Working Cap
Days ⓘ
01152111810
Cash Conv.
Cycle ⓘ
0801601320

Valuation of Speciality Medicines - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'22Mar'23Mar'24Mar'25Mar'26
Sales4023285875
Operating Expenses ⓘ + 3820224962
Manufacturing Costs00000
Material Costs3516184254
Employee Cost 11111
Other Costs ⓘ 22366
Operating Profit ⓘ 245914
Operating Profit Margin (%) 5.6%15.4%19.2%15.7%18.2%
Other Income ⓘ + 00001
Exceptional Items ⓘ 00000
Interest ⓘ 00111
Depreciation ⓘ 00000
Profit Before Tax ⓘ 235913
Tax ⓘ 1121-0
Profit After Tax 123713
PAT Margin (%) 3.7%7.3%10.7%12.4%17.3%
Adjusted EPS (₹)4.74.45.711.214.8
Dividend Payout Ratio (%)0%0%0%0%0%
PARTICULARSMar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 26153171
Share Capital ⓘ 0.213.825.126.448.79
Reserves ⓘ 22102462
Debt +13345
Long Term Debt01135
Short Term Debt12210
Minority Interest00000
Trade Payables122112
Others Liabilities ⓘ 13357
Total Liabilities ⓘ 613234095

Fixed Assets

Net Fixed Assets ⓘ +22122
Gross Block22233
Accumulated Depreciation00111
CWIP ⓘ 00000
Investments ⓘ 00000
Inventories0581728
Trade Receivables36111027
Cash Equivalents flag ⓘ 000125
Others Assets ⓘ 0121014
Total Assets ⓘ 613234095
PARTICULARSMar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 1-4-5-6-1
PBT ⓘ 235913
Adjustment ⓘ 01111
Changes in Working Capital ⓘ -1-7-9-14-16
Tax Paid ⓘ 0-1-1-10
Cash Flow From Investing Activity ⓘ + -20-0-1-3
Capex -2-0-0-1-0
Net Investments -000-0-0
Others ⓘ -0-00-1-3
Cash Flow From Financing Activity ⓘ + 245828
Net Proceeds from Shares ⓘ 026729
Net Proceeds from Borrowing ⓘ 01-122
Interest Paid ⓘ -0-0-1-0-1
Dividend Paid ⓘ 00000
Others ⓘ 1100-2
Net Cash Flow ⓘ 00-0124
PARTICULARSMar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)76.5643.328.0331.525.6
ROCE (%)69.7552.4137.7234.3425.26
Asset Turnover Ratio72.441.531.861.11
PAT to CFO Conversion(x)1-2-1.67-0.86-0.08
Working Capital Days
Receivable Days23.4063.60107.5063.6087.50
Inventory Days4.4039.9083.7079.60110.80
Payable Days12.3033.5042.3014.7043.50

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Annual reports

No annual reports available.

Concalls

No concalls available.

Speciality Medicines Ltd FAQs

The current trading price of Speciality Medicines on 02-Nov-2026 16:59 is ₹140.0.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Nov-2026 the market cap of Speciality Medicines stood at ₹123.0 Cr

The latest P/E ratio of Speciality Medicines as of 01-Nov-2026 is 9.44.

The latest P/B ratio of Speciality Medicines as of 01-Nov-2026 is 1.73.

The 52-week high of Speciality Medicines is ₹381.2 and the 52-week low is ₹121.1.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Speciality Medicines is ₹75.28 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Speciality Medicines Ltd is a below average quality company.

The key valuation ratios of Speciality Medicines Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Speciality Medicines Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Speciality Medicines Ltd

Speciality Medicines was originally incorporated as ‘Speciality Medicines Private Limited’ as a Private Limited Company on February 05, 2021. Later on, pursuant to a special resolution passed by its shareholders in the extra-ordinary general meeting held on April 04, 2024, the company was converted from a private limited company to public limited company and consequently, the name of the company was changed from ‘Speciality Medicines Private Limited’ to ‘Speciality Medicines Limited’ on June 25, 2024.

It is engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. It offers a diverse portfolio of specialty pharmaceutical products, focusing on various therapeutic areas such as oncology, immunology, neurology, and rare diseases. Its products which are offered in such areas are available in a wide range of dosage forms like Tablets, Capsules, Cream, Syrups, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nasal Spray, Ointment, Ophthalmic, Oral Solution, Oral Suspension, Sachet and Suspension. It operates through two integrated business models: (a) Manufacturing, through contract manufacturing basis, of approved finished formulations and distribution internationally and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers.

Under its contract manufacturing arrangement, its contract manufacturer based in India is responsible for the manufacturing of speciality pharmaceutical formulations. These formulations are either approved or currently undergoing the approval process with the relevant health authorities in the target countries. Once the necessary regulatory approvals are obtained, it initiates its role as the distributor for these products. Its responsibilities include overseeing the marketing and distribution of the approved specialty pharmaceutical products across multiple international markets. Under its other business model, it operates as a distributor of specialty pharmaceutical products sourced from manufacturers. Its role focuses on the procurement, warehousing, and wholesale distribution of these medicines to a wide network of healthcare providers and retailers. It ensures smooth supply chain operations and timely delivery across various regions. Its services are centred on maintaining consistent product availability and supporting its customers through reliable and efficient distribution.

Business area of the company

The company is primarily engaged in the business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising of high-cost oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. Its products are supplied to both domestic and international markets.

Products categories of the company

  • Anti-Cancer: Medicines for prevention, control, or treatment of different types of cancers including solid tumours and blood cancers. 
  • Vaccines (Human & Veterinary): Preventive 155mmunization products to protect humans and animals from viral and bacterial diseases. 
  • Critical Care: High-urgency medicines used in intensive care units for life-saving interventions and severe medical conditions. 
  • Anti-Diabetic: Therapies to manage blood glucose levels in patients with Type 1 and Type 2 diabetes.
  • Gynecology: Medicines for women’s reproductive health, hormonal balance, and pregnancy-related conditions. 
  • Nephrology: Treatments for chronic kidney diseases, dialysis support, and electrolyte management.
  • Dermatology: Medications for skin infections, inflammatory skin disorders, and dermatological maintenance.
  • Anti-Hypertensive: Drugs to control high blood pressure and prevent related cardiovascular complications.
  • Anti-Malarial: Medicines for the prevention and treatment of malaria caused by Plasmodium parasites.
  • Antibiotics (Human & Veterinary): Broad- and narrow-spectrum drugs to treat bacterial infections in humans and animals.
  • Antiviral Therapies: Targeted treatments for viral infections such as Hepatitis B, Hepatitis C, HIV, COVID19, and Influenza.
  • Chronic & Autoimmune Disorders: Long-term disease management including thyroid disorders, arthritis, and autoimmune-related inflammation. 
  • Ophthalmic Care: Treatments for eye conditions such as glaucoma, infections, and vision-related issues.
  • Anti-TB: Multi-drug regimens for the treatment and eradication of tuberculosis. 
  • Steroid Therapy: Anti-inflammatory and immunosuppressive medicines used in acute and chronic conditions.
  • Anti-Fungal: Drugs to prevent or treat fungal infections affecting skin, nails, and internal organs.
  • Ayurvedic & Herbal: Herbal formulations and alternative medicines for wellness and therapeutic support.
  • Erectile Dysfunction: Medicines to improve male sexual function and address erectile disorders.
  • Dental Products: Products for oral hygiene, dental infection control, and gum disease management.
  • Vitamins & Supplements: Nutritional support products, including vitamin and mineral supplements, for overall health maintenance.
  • Surgical Products: Supplies and consumables used in surgical procedures and hospital care.
  • Symptom Relief: Medicines to reduce fever, pain, and other common discomforts.

History and milestones

  • 2021: Incorporation of the company viz. ‘Speciality Medicines Private Limited’.
  • 2021: The company shifted its operation to Mumbai, Maharashtra, India 
  • 2022: The company was recognized as Start-up by Department for Promotion of Industry and Internal Trade 
  • 2023: The company received certificate as an eligible business by Inter-Ministerial Board to avail Income Tax benefits under Section 80-IAC of the Income Tax Act, 1961.
  • 2024: Conversion of the company from private limited to public limited company.

You have 3 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now